Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

Non-Hodgkin’s lymphoma (NHL) is the sixth most common cause of cancer deaths in the U.S. Most NHLs initially respond well to chemotherapy, but relapse is common and treatment is often limited due to the toxicity of chemotherapeutic agents. Pegylated-liposomal doxorubicin (PLD, Ben Venue Laboratories...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donnell, Robert T., Martin, Shiloh M., Ma, Yunpeng, Zamboni, William C., Tuscano, Joseph M.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2009
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850518/
https://www.ncbi.nlm.nih.gov/pubmed/19306119
http://dx.doi.org/10.1007/s10637-009-9243-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850518/
https://www.ncbi.nlm.nih.gov/pubmed/19306119
http://dx.doi.org/10.1007/s10637-009-9243-7

Ejemplares similares